Upland, CA (PRWEB) July 16, 2012
Claremont BioSolutions, LLC announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the NIH/NIAID. The $3M award, entitled “A fully integrated assay and platform for detecting Clostridium difficile” will fund a collaborative effort coordinated by ClaremontBio. Collaborators include Angelika Niemz at the Keck Graduate Institute (http://www.kgi.edu) in Claremont, CA, David Boyle at Seattle-based PATH (http://www.path.org), and Ciaran Kelly at the Beth Israel Deaconess Medical Center.
“The NIH award will allow us to develop a small bench-top device to detect Clostridium difficile both in patients and from potentially contaminated surfaces in healthcare facilities. C. difficile is now the most common hospital-acquired infection and has become a major cost factor in hospitals and nursing homes,” commented ClaremontBio’s Chief Technology Officer, Bruce Irvine. “The instrument which will be developed under this award will allow rapid, near-patient diagnosis of C. difficile, benefitting both the patient and the healthcare facility by cutting the time to treatment and reducing the threat of facility contamination.” He continued, “The same instrument will also help facilities reduce costs by using it to monitor and then react immediately to any contamination problems.”
ClaremontBio’s CEO, Dr. Gary Blackburn, commented that “we welcome this ‘validation’ of our technologies following our successful completion of the Phase I SBIR award last year. We have a new approach to sample prep that will deliver diagnostic answers rapidly to caregivers, researchers, and technicians in a wide range of environments and industries.”
About Claremont BioSolutions.
Claremont BioSolutions (http://www.ClaremontBio.com) is an emerging growth diagnostics company with unique solutions to the “bottleneck” of sample preparation that is an essential first step to any DNA or RNA diagnostic test. The company has pioneered efforts to integrate sample preparation into sample-to-answer disposable cartridges as the front-end to nearly any amplification and detection scheme co-integrated into the same cartridge. ClaremontBio’s devices impart mechanical energy directly to the fluid to lyse cells and extract DNA or RNA and, for some application, fragment or shear the nucleic acid in a controlled fashion. The sample prep process is complete in less than five minutes and requires only a battery pack, no other instruments.
Contact Name: Bruce Irvine
Claremont BioSolutions, LLC
Phone: (877) 920-3887
Fax: (909) 946-1132
Address: 1182 Monte Vista, Ave., Suite #11
Upland, CA. 91786